Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

Published:2012-04-19 Issue:1 Volume:4 Page:151-157
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:en
Short-container-title:

Author:

HONG JIDONG,PENG YUPING,LIAO YUPING,JIANG WUZHONG,WEI RUI,HUO LEI,HAN ZAIDE,DUAN CHAOJUN,ZHONG MEIZUO

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma;Cancer Letters;2024-06

2. Current approaches in glioblastoma multiforme immunotherapy;Clinical and Translational Oncology;2024-03-21

3. Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment;Advanced Healthcare Materials;2024-03-07

4. Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?;Cancers;2022-11-30

5. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms;Vaccines;2022-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP